Healthcare M&A and Valuation Multiples in Q2 2026

A single sector average is of little use in healthcare. Valuations are determined less by the label above a business than by the quality of the earnings beneath it — how recurring the revenue is, how hard the product is to displace, and how cleanly profit converts to cash. Those attributes vary so widely across the sector that two businesses on identical margins can command multiples that differ by half. This note sets out where value sits across eight healthcare subsectors, and what separates the businesses the market pays up for from those it does not.

Key takeaways

• Across 75 listed healthcare businesses that we have analysed (excluding pharma and biotech), the median trades at about 12.8x EV/EBITDA 2026E — subsector medians run from 7x for care-home operators and 8x for hospitals to nearly 17x for diagnostics and life-science tools.
• The ranking tracks earnings quality — recurring razor-and-blade revenue, switching costs and cash conversion — over headline growth and margins.
• M&A is above the screen for specified, IP-rich assets: 2025–26 diagnostics and device deals cleared roughly 19–20x EBITDA, while commodity-like providers and distributors change hands in the high single digits.
• For UK businesses, the listed screen is largely US. The relevant read is where a UK business sits within that range.

The backdrop: a selective, de-rated, still-active market

Healthcare enters the second half of 2026 as a market that has cooled on price but not on activity. On the listed side, sector multiples have compressed for three years running — the broad healthcare screen now sits around 12–13x EBITDA, down from the mid-teens two years ago, as higher rates, drug-pricing policy and softer research funding took the premium out of the group. On the deal side, the story is the opposite of quiet: 2025 closed with over 950 healthcare transactions, and the first quarter of 2026 was one of the strongest on record, led by a wave of large-cap portfolio reshaping.

Strategic buyers are paying full, sometimes exceptional, prices for assets that deepen a specified, hard-to-replace position — a diagnostics franchise, a category-leading device, a specialist manufacturing capability. Everything more commoditised — volume distribution, general contracting of care, capital-intensive processing — is being valued on cash flow and increasingly bought by financial sponsors and property investors running a buy-and-build or income playbook.

What the healthcare trading comparables say

The table below shows the median EV/EBITDA 2026E for each of the eight healthcare subsectors, alongside the operating metrics that drive the ranking. The order is driven, beyond headline margin and growth, by earnings quality — how recurring, defensible and cash-generative the revenue is.

Healthcare — Median EV/EBITDA 2026E by Subsector

Bar chart of median EV/EBITDA 2026E by healthcare subsector, from 7x for care homes to 16.9x for diagnostics and life-science tools, with the operating metrics that drive the ranking.

This explains why pharmacy & distribution screens high at 14.8x on thin 1.5–2.0% margins, driven by low-risk, high-volume operations, strong capital efficiency, and consistent share buybacks. The same story applies to managed care.

Diagnostics & life-science tools — the high-value picks and shovels

These are the "picks-and-shovels" of medicine — the instruments, reagents, consumables and bioprocessing kit that laboratories and drug-makers design into a validated workflow and then buy, repeatedly, for years. The internal spread is wide and instructive: Mettler-Toledo trades at 22.7x while bioMérieux, on comparable margins and stronger growth, trades at barely a third of that (8.4x). The gap is not explained by the headline numbers — it is explained by three things underneath them. The first is the installed-base service annuity. Mettler-Toledo has more than 20 million instruments in the field and has penetrated only about a third of the roughly $3bn of serviceable recurring revenue they represent; every unit sold pulls through years of calibration, service and software at high margin. bioMérieux, by contrast, is a single-play in-vitro diagnostics business whose growth, while real, is tied to test volumes and reimbursement decisions it does not control — a structurally less certain revenue stream that earns a lower multiple even at a similar margin. The second factor is pricing power and customer diffusion: no single Mettler-Toledo customer is more than 1% of revenue, and its regulated-market position lets it price ahead of inflation; a diagnostics business selling into hospital labs and public health systems has far less of both. The third is simply listing and mix: a US-listed, diversified compounder attracts a premium that a European-listed, single-category name does not. The multiple follows the durability and ownership of the revenue annuity, not the current margin — two businesses earning ~30% margins can be valued three times apart. The cheaper names in the bucket — Labcorp and Quest at 11–13x — are the lab-services businesses, closer to volume processing than to specified tools, and the market prices that difference precisely.

Diagnostics & Life-Science Tools — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency. Shaded cells at or above the peer-set median.

CRO / CDMO — the outsourced pharma engine

At a median of 14.2x, the businesses that run clinical trials and manufacture drugs under contract are valued for a structural tailwind: pharma continues to outsource more of its research and production, and specialist capacity — sterile injectables, complex biologics, radiopharmaceuticals — is genuinely scarce. The spread inside the bucket, from Siegfried at 11.8x to Dottikon at 31.6x, is unusually wide, and three specific factors explain it. The first is backlog visibility: a CRO or CDMO with multi-year booked revenue and high repeat rates from blue-chip sponsors has earnings a buyer can underwrite years out, and the market pays for that certainty; Medpace (24.7x) trades on the cleanest backlog in the set. The second is modality scarcity: capacity for GLP-1 sterile fill-finish, high-potency and radiopharmaceutical work is constrained and cannot be added quickly, so the specialists (Dottikon, Bachem) command premiums that generalist trial-services businesses do not. The third is customer concentration and cyclicality: names weighted to early-stage biotech funding — Fortrea (14.6x) — carry more volatile, discretionary demand and are marked down for it. In short, the market is not paying for "contract manufacturing"; it is paying for booked, scarce, non-cyclical capacity, and discounting everything short of that.

CRO / CDMO (Pharma Services) — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency. Shaded cells at or above the peer-set median.

Medical equipment & devices — broad and bifurcated

From Philips at 8.4x to Intuitive Surgical at 22.2x, the gap is not about growth or margin alone. It is about the razor-and-blade structure of the revenue. The businesses at the top sell an installed platform that then pulls through years of high-margin recurring consumables and service: every Intuitive robot placed generates a stream of instrument and accessory revenue the hospital cannot substitute, and Edwards' (21.5x) structural-heart valves sit inside a procedure franchise with clinical switching costs measured in surgeon retraining. That recurring, locked-in pull-through is what a strategic acquirer will pay a premium for, because it is the hardest thing to build. The businesses at the bottom — Philips (8.4x), GE HealthCare (9.9x), Siemens Healthineers (11.7x) — sell big-ticket capital equipment on long, lumpy replacement cycles exposed to hospital capex budgets; Zimmer Biomet (8.9x) and Baxter (9.2x) carry mature, price-pressured product lines with little recurring hook. Same sector, same margins in several cases, but one model compounds and the other re-sells itself every cycle. The two UK names sit in the value half, Smith & Nephew (9.6x) and ConvaTec (10.5x), both below the median and both illustrations of the UK discount that keeps cross-border interest in UK medtech live.

Medical Equipment & Devices — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency. Shaded cells at or above the peer-set median.

Managed care and providers — two sides of one transaction

Managed care (10.1x) is the US health insurers — UnitedHealth, Cigna, Elevance — who collect premiums and bear medical-cost risk; their margins are tiny (4–5%) because their "cost of goods" is the claims they pay. Providers (8.0x) are the ones actually delivering care — hospitals, dialysis, rehab — who get paid by those insurers; their margins are structurally higher (HCA at 20%, Tenet in the low-20s) because they sell a service at a mark-up rather than underwriting risk. Money flows payer to provider, and the two are valued on entirely different logic.

Within the provider bucket itself the spread is driven by three things, and payer mix is the largest. A hospital's earnings quality is set by who pays for the care: commercially-insured patients reimburse at materially higher rates than Medicare or Medicaid, so a provider with a rich commercial mix earns a higher, more defensible margin and a higher multiple — the same reason HCA (~20% margins, favourable payer mix, and a growing exchange population) trades at a premium to peers with heavier government-pay exposure. The second factor is scale and site mix: large multi-hospital systems with owned outpatient and ambulatory-surgery capacity capture more of the care pathway and flex costs better than single-site or purely inpatient operators, which is part of why the market prefers HCA to a discounted Tenet even as both grow. The third is service concentration: a single-service, capital-intensive, government-reimbursed operator such as DaVita (dialysis) carries reimbursement and concentration risk that a diversified acute system does not, and sits lower as a result. Capital intensity and working-capital demands sit underneath all three — providers are asset-heavy and cash-consumptive, which is why the bucket as a whole trades below the specified, recurring-revenue tiers regardless of margin.

For a UK reader this split is largely academic on the payer side and central on the provider side. The UK has no listed payer equivalent — the NHS is the payer, and it is not investable. UK healthcare exposure is a provider story, and it has been the most active corner of the UK-listed market this year. Spire Healthcare, the UK's largest private hospital operator, spent 2026 as a live take-private situation: a strategic review opened in September 2025, private-equity bidders (Bridgepoint, Triton) circled through the first quarter before walking away in March, and a fresh approach around 250p — valuing the equity north of £1bn — emerged in May. Spire trades around 8x, in line with the global provider median but at a persistent discount to the value of its freehold hospital estate — which is precisely what has drawn the buyers.

Managed Care / Payers — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency. Shaded cells at or above the peer-set median.

Providers & Care Delivery — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency. Shaded cells at or above the peer-set median.

Care homes & senior living — operations and real estate

The internal spread — Clariane at 5.3x to Ensign at 16.2x, a three-fold range — looks extreme until one sees what drives it: whether the operator owns or leases its real estate. A care business splits into two economically different things stacked on top of each other — the property (a long-duration, inflation-linked income asset that trades on a low cap rate, i.e. a high multiple) and the operating business (a staffing- and occupancy-driven service that trades on a much lower multiple). Ensign (16.2x) screens high because it owns a large freehold estate and its structure and growth flatter the blended figure; Brookdale (7.0x) and France's Clariane (5.3x, formerly Korian) are far more operationally geared — leaseholders or restructuring operators carrying rent and thin operating margins — and the market values them as the service businesses they largely are. The multiple observed therefore depends almost entirely on how much freehold sits inside the entity. Clariane makes the point from the other direction: it has spent the last two years selling real estate to reduce the owned-asset share of its balance sheet, precisely because the market values the property and the operations so differently. In the UK, almost none of this value is listed at all: it is private, or held through property structures.

Care Homes & Senior Living — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency. Shaded cells at or above the peer-set median.

The proof was the largest UK healthcare transaction of the cycle. In late 2025 the US REIT Welltower acquired the real-estate portfolios behind Barchester (£5.2bn, the largest care-home deal in the world to date) and HC-One (£1.2bn) — over £6bn combined — leaving the operating brands in place under long-term partnership structures. The CMA opened a phase-one review in early 2026, and the wider UK healthcare-property market was on track for a record ~£12bn of deal volume, boosted further by Primary Health Properties' £1.79bn acquisition of Assura. The read-through for a UK care-home owner is clear: the buyer universe is dominated by international capital and property investors valuing durable, demographically-underpinned income.

Health IT, pharmacy & distribution — the value and volume ends

Health IT mixes high-margin vertical software with sub-scale, loss-making platforms. Veeva (18.5x) and Doximity (9.9x on a ~55% margin) are the quality anchors — genuine software economics, high retention, strong cash generation. Hims & Hers (20.2x) is priced for consumer-health growth. Much of the rest — Teladoc, Health Catalyst, Evolent — sits in single digits, where the equity story is everything and profitability is still being proven. M&A here has been about buying "reimbursement rails and regulatory option value," not just revenue: Waystar's $1.25bn purchase of Iodine Software, Roper's $1.65bn CentralReach deal, and Hims's $1.15bn acquisition of Australia's Eucalyptus for international reach.

Pharmacy & distribution (14.8x) is the volume floor dressed up by a thin-margin optic. McKesson, Cencora and Cardinal Health move over 90% of US prescription volume on ~1.5% margins; the high multiple reflects vast, stable, low-risk throughput, not pricing power. Their growth story is vertical integration — the big three have spent over $16bn buying oncology and specialty physician networks to secure downstream demand — against a persistent opioid-litigation overhang. It is a capital-light, systemically essential, low-margin model, and it is valued exactly as such.

Health IT & Digital Health — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency. Shaded cells at or above the peer-set median. Tempus AI (125.0x on near-zero EBITDA) is excluded from the median as an outlier.

Pharmacy & Distribution — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency. Shaded cells at or above the peer-set median.

What healthcare business acquirers actually paid

The transactions of the last eighteen months confirm the ranking the screen implies, and add the detail listed medians cannot: what buyers pay for control. The deals that got done cluster above where each subsector trades, because acquirers pay up precisely for the specified, recurring, hard-to-replace earnings the market already prizes. Broken out by vertical, the pattern is consistent — and the disclosed EBITDA multiples show just how far the premium runs at the specified end.

Healthcare M&A — Selected Recent Precedents, by Subsector

¹ Reported; ~15x on normalised EBITDA.

² Struck on ~8x revenue given modest current EBITDA.

³ On ~$75m EBITDA for the year to Jun-26.

⁴ Reverse Morris Trust spin-merge.

⁵ On 2027E EBITDA; ~15x including full run-rate synergies.

Source: company announcements, SEC filings and press reports. EBITDA margin is the target's at announcement where reported. "n/d" means not disclosed. Illustrative — does not constitute advice.

Read down the multiples and the thesis holds without further comment: the specified diagnostics and monitoring assets cleared at roughly 19–31x, the differentiated CDMO at ~15x normalised (23x reported), the recurring-revenue software platforms in the low-to-mid 20s, and the one high-growth device deal (Inari) struck on revenue because its current EBITDA was deliberately reinvested. Buyers paid for what the earnings are — recurring, specified and hard to replace — not for the sector label they sit under.

What this means if you are considering a sale

The subsector sets the starting line, not the outcome. The 7x-to-17x spread on the screen is the same spread a private buyer will pay between a commoditised care-delivery business and a specified, recurring-revenue diagnostics or device franchise. Listed multiples are the floor for the conversation, not the answer. A proper valuation starts by establishing where a business sits on that quality ladder — and building the evidence for why a buyer should pay above the quoted peer set.

Earnings quality does the heavy lifting. Across every bucket, the businesses that command premium multiples share the same attributes: recurring razor-and-blade revenue, high switching costs, clean cash conversion, and a product or position that is hard to substitute. A device with an installed base and consumable pull-through, a lab with a specified assay, a care business with durable occupancy and freehold backing — these are valued like different businesses from their commoditised peers, and they should be presented that way to buyers.

For UK owners, the buyer pool is wider than the screen suggests. The listed comparables are overwhelmingly US, and UK-listed healthcare is thin — which is exactly why cross-border strategics and financial sponsors are so active in UK medtech, private hospitals and care homes. A process that only tests domestic buyers, or that anchors on a UK-listed multiple, is likely to leave material value on the table. The most active recent UK healthcare deals were all done by international capital paying for assets the London market had under-valued.

To see how these subsector medians sit against every other sector we track, benchmark where your business sits using our valuation multiples tool.

Frequently asked questions

What EV/EBITDA multiple do healthcare businesses trade at in 2026?

Across ~75 listed healthcare businesses (excluding pharma and biotech) the median is about 12.8x EV/EBITDA 2026E, but subsector medians run from roughly 7x for care-home operators and 8x for hospitals to nearly 17x for diagnostics and life-science tools.

Why do diagnostics and life-science tools businesses trade at higher multiples than hospitals or care homes?

Because their earnings are more recurring and harder to replace — instruments and consumables designed into a validated workflow carry high switching costs, a large installed-base service annuity, and strong cash conversion, whereas hospitals and care homes are capital-intensive, occupancy-driven and more exposed to reimbursement.

What multiples are healthcare M&A deals clearing at?

Specified, IP-rich diagnostics and device deals in 2024–2026 cleared roughly 19–27x EBITDA (for example Abbott/Exact Sciences and Boston Scientific/Penumbra), recurring-revenue software in the low-to-mid 20s, while commoditised or capital-intensive assets change hands far lower.

How are UK private hospitals and care homes valued?

UK private hospitals trade around 8x EBITDA (Spire), often at a discount to their freehold estate; UK care-home value is mostly private or held in property structures — the largest recent deals (Welltower's £5.2bn Barchester and £1.2bn HC-One purchases) were real-estate transactions priced on property yields, not listed EBITDA multiples.

Why do two healthcare businesses with the same margin sell for very different multiples?

Because the multiple follows the quality of the earnings, not the margin: recurring revenue, high switching costs, clean cash conversion and a hard-to-replace product command a premium, while commoditised, reimbursement- or capital-dependent earnings do not — the difference can be three-fold even at similar margins.

Are the listed multiples a good benchmark for a UK healthcare business?

They set the starting line, not the answer. The listed screen is overwhelmingly US, UK-listed healthcare is thin, and cross-border and financial buyers are unusually active — so a UK owner should benchmark where their business sits within the range and test international buyers rather than anchor on a single UK multiple.

Where does a business sit on the ladder?

Deal Ascent maintains one of the most extensive healthcare valuation-benchmark databases in the UK mid-market. For owners weighing a sale, an approach or succession, we can benchmark where a business sits and how buyers are likely to value it.

This note is intended for information purposes only and does not constitute financial, tax or legal advice. Valuation multiples are based on consensus estimates for listed peer groups as of July 2026 and are provided for directional context only. Small peer sets (notably payers, care homes and pharmacy & distribution) yield directional medians rather than precise benchmarks. Private-company transactions will differ. Deal Ascent is an appointed representative and is authorised and regulated in the conduct of relevant activities. Specific professional advice should be sought before making any business or financial decision.